Cerus, headquartered in Concord, California, focuses on developing the INTERCEPT Blood System to enhance blood safety by reducing pathogens in transfusion blood components. The company employs 288 people and specializes in various blood products.
CERS has been in the news recently: Cerus Corporation has secured a $248 million contract with BARDA to advance its INTERCEPT RBC program in the U.S. while addressing regulatory issues in Europe. The company will also release its Q3 2024 financial results on October 30, 2024, and present research at the AABB Annual Meeting from October 19-22, 2024.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
